FY2024 Earnings Estimate for GRI Bio Issued By HC Wainwright

GRI Bio, Inc. (NASDAQ:GRIFree Report) – Research analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for GRI Bio in a research report issued on Monday, December 9th. HC Wainwright analyst M. Keller forecasts that the company will earn ($3.04) per share for the year. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. HC Wainwright also issued estimates for GRI Bio’s Q4 2024 earnings at ($0.40) EPS, FY2025 earnings at ($0.90) EPS, FY2026 earnings at ($0.68) EPS, FY2027 earnings at ($0.38) EPS and FY2028 earnings at ($0.31) EPS.

Separately, Ascendiant Capital Markets upped their target price on GRI Bio from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Thursday, December 5th.

Check Out Our Latest Research Report on GRI

GRI Bio Price Performance

Shares of NASDAQ GRI opened at 0.93 on Tuesday. GRI Bio has a 12 month low of 0.30 and a 12 month high of 65.00. The business has a 50-day moving average of 0.70 and a 200-day moving average of 1.24.

Hedge Funds Weigh In On GRI Bio

A hedge fund recently bought a new stake in GRI Bio stock. Armistice Capital LLC acquired a new position in GRI Bio, Inc. (NASDAQ:GRIFree Report) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 50,207 shares of the company’s stock, valued at approximately $96,000. Armistice Capital LLC owned approximately 9.23% of GRI Bio at the end of the most recent quarter. 33.95% of the stock is currently owned by institutional investors and hedge funds.

About GRI Bio

(Get Free Report)

GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.

Recommended Stories

Receive News & Ratings for GRI Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRI Bio and related companies with MarketBeat.com's FREE daily email newsletter.